Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

PCSK9 Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PCSK9 (11) CX3CR1 (2) HMG Family (2) Keap1-Nrf2 (2) LDLR (1) NF-κB (3) NOD-like Receptor (NLR) (2) Ser/Thr Protease (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (6) Endocrinology (1) Inflammation/Immunology (3) Metabolic Disease (5)

Inhibitors & Agonists

Inhibitory Antibodies

Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) PCSK9 ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9928A

*Alirocumab (anti-PCSK9)* 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits *PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

HY-P99822

Recaticimab SHR-1209	PCSK9 LDLR	Metabolic Disease
Recaticimab (SHR-1209) is an orally active humanized monoclonal IgG1 antibody targeting *PCSK9. Recaticimab binds PCSK9* with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .

HY-P99187

Bococizumab PF-04950615; RN316	PCSK9	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P99552

Tafolecimab IBI-306	PCSK9	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds *PCSK-9* and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-P990485

**Anti-PCSK9 Antibody**	PCSK9	Inflammation/Immunology
Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting *PCSK9. Anti-PCSK9* Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits PCSK9* binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99251

Lodelcizumab	PCSK9	Others
Lodelcizumab is a monoclonal antibody targeting *PCSK9*. Lodelcizumab can be used for the research of hypercholesterolemia .

HY-P991343

ALD306 ALD309	PCSK9	Endocrinology
ALD306 is a human monoclonal antibody (mAb) targeting *PCSK9*. ALD306 can be used in Hypercholesterolaemia research .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99871

Ebronucimab AK102	PCSK9	Others
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits *PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9* protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits *PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .

Cat. No.	Product Name	Target	Research Area

HY-P9928A

*Alirocumab (anti-PCSK9)* 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits *PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

HY-P99822

Recaticimab SHR-1209	PCSK9 LDLR	Metabolic Disease
Recaticimab (SHR-1209) is an orally active humanized monoclonal IgG1 antibody targeting *PCSK9. Recaticimab binds PCSK9* with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .

HY-P99187

Bococizumab PF-04950615; RN316	PCSK9	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P99552

Tafolecimab IBI-306	PCSK9	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds *PCSK-9* and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-P990485

**Anti-PCSK9 Antibody**	PCSK9	Inflammation/Immunology
Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting *PCSK9. Anti-PCSK9* Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits PCSK9* binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99251

Lodelcizumab	PCSK9	Others
Lodelcizumab is a monoclonal antibody targeting *PCSK9*. Lodelcizumab can be used for the research of hypercholesterolemia .

HY-P991343

ALD306 ALD309	PCSK9	Endocrinology
ALD306 is a human monoclonal antibody (mAb) targeting *PCSK9*. ALD306 can be used in Hypercholesterolaemia research .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99871

Ebronucimab AK102	PCSK9	Others
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits *PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9* protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits *PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .

HY-P990658

RG-7652	Inhibitory Antibodies	Inflammation/Immunology

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81805

	PCSK9 Antibody (YA1550) HCHOLA3; LDLCQ1; NARC1; Neural apoptosis regulated convertase 1; PC9; PCSK9; Proprotein convertase 9	WB, IP	Human
	PCSK9 Antibody (YA1550) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1550), targeting PCSK9, with a predicted molecular weight of 74 kDa (observed band size: 65/80 kDa). PCSK9 Antibody (YA1550) can be used for WB, IP experiment in human background.

HY-P85725

	PCSK9 Antibody (YA5417) Proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9	IHC-P	Human

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.